Cefditoren Pivoxil

Summary

Cefditoren Pivoxil (CHEMBL454446) is an approved small-molecule prodrug; indicated across 5 conditions including chronic bronchitis and tonsillitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 4
• Chemistry: 620.7 Da · C25H28N6O7S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL454446
Name	Cefditoren Pivoxil
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6437877
ChEBI	CHEBI:560555
Molecular formula	C25H28N6O7S3
Molecular weight	620.7
InChIKey	AFZFFLVORLEPPO-UVYJNCLZSA-N

SMILES: CC1=C(SC=N1)/C=C\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C

IUPAC name: 2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

ChEBI definition: The pivaloyloxymethyl ester prodrug of cefditoren.

Pharmacological roles (ChEBI): prodrug, antibacterial drug.

Also known as: CDTR-PI, Cefditoren pivaloyloxymethyl ester, Cefditoren pivoxil, ME-1207, ME1207, Meiact, NSC-759098, Spectracef, Cefditoren, cefditoren, SID26749056, CEFDITOREN PIVOXIL

Patent coverage: 867 distinct patent families (3,185 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Cytochrome P450 3A4, Aldehyde dehydrogenase 1A1, Prolyl endopeptidase FAP.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FAP	7.19	IC50	65	nM	CHEMBL_ACT_29108091
FAP	6.82	Ki	150	nM	CHEMBL_ACT_29108078
ALDH1A1	6.45	Potency	354.8	nM	CHEMBL_ACT_4125136
CYP3A4	5.4	Potency	3981	nM	CHEMBL_ACT_4985699
CYP3A4	5.4	Potency	3981	nM	CHEMBL_ACT_5054688

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
chronic bronchitis	4	MONDO:0005607	EFO:0006505
tonsillitis	4	MONDO:0001039	HP:0011110
pharyngitis	4	MONDO:0002258	MONDO:0002258

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
urinary tract infection	3	MONDO:0100338	EFO:0003103

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01553006	PHASE4	UNKNOWN	Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis
NCT04709172	PHASE4	COMPLETED	Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia
NCT00598403	PHASE3	COMPLETED	Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis
NCT06644105	Not specified	COMPLETED	Pharmacokinetic Study of Cefditoren Pivoxil in Breast Milk and Blood of Lactating Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).